{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-21-000029","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.132714+00:00","generated_at":"2026-06-28T13:15:26.603458+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis","bullets":["Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.","Submitted NDA to FDA for roflumilast cream for plaque psoriasis based on Phase 3 DERMIS trials.","Initiated pivotal Phase 3 trial of roflumilast foam in scalp/body psoriasis; topline expected H2 2022.","Terminated Phase 2a trial of ARQ-252 in vitiligo due to inadequate local drug delivery.","R&D expense $40.6M vs $32.7M YoY; G&A expense $16.5M vs $5.6M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-21-000029","json":"https://secwatch.observer/filing/0001787306-21-000029.json","markdown":"https://secwatch.observer/filing/0001787306-21-000029.md","text":"https://secwatch.observer/filing/0001787306-21-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/0001787306-21-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/arqt-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:15:26.603458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}